ARTICLES BY RONALD A. RADER

• Cell & Gene Therapy Bioprocessing: Demand For Better Process Control, Expertise & CMOs

  5/14/2021

  Manufacturing capacity for both cell therapies and gene therapy viral vectors remains in short supply. From BioPlan Associates, Inc.'s new survey of biopharmaceutical manufacturing professionals, there is a current and worsening capacity crunch. The industry continues to demand innovative solutions from its suppliers in key areas that can be slow to develop. 

• The “New Normal”: Changing Perceptions on Bioprocess Intensification and Continuous Bioprocessing

  3/1/2021

  Process intensification and continuous bioprocessing are concepts with inconsistent definitions. What's included often varies greatly and, in some ways, has become more about aspirational goal-setting than actual innovation adoption. Here, BioPlan Associates assesses the changing perspectives of 122 bioprocess decision-makers.

• Bioprocessing Year In Review: 11 Key Trends Accelerated By COVID-19

  12/11/2020

  Despite the morbidity, deaths, and terrible societal disruptions associated with the COVID-19 pandemic, 2020 will have created something of a positive outcome for the bioprocessing sector.

• COVID-19's Impact On Bioprocessing: Insights From Industry Leaders

  8/5/2020

  We interviewed 26 biopharma senior executives regarding how they are handling the crisis and its long-term impact on their operations. We found the pandemic has begun to catalyze and accelerate a number of significant changes, including many preexisting trends.

• Biosimilars Pipeline Analysis: Many Products, More Competition Coming

  7/26/2016

  Our discussion of biosimilars in this article will center on developed-market GMP biosimilars. In the European market alone, biosimilars already are a multibillion-dollar business, and one that is rapidly growing.